Related Experiment Video
Updated: Sep 8, 2025
A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
Ulcerative colitis in patients with sickle cell disease: a rare but important co-morbidity
1Sickle Cell Unit, Caribbean Institute for Health Research, The University of the West Indies, Kingston, Jamaica.
Insights
This study analyzes COVID-19's impact on pediatric inflammatory bowel disease (IBD) patients, comparing outcomes in high-income countries (HIC) and low- and middle-income countries (LMIC). Findings highlight disparities in disease management and severity.
Area of Science:
- Pediatric gastroenterology and infectious diseases.
- Comparative health outcomes research.
- Global health equity in chronic illness management.
Background:
- The COVID-19 pandemic has presented unique challenges for managing chronic pediatric conditions like inflammatory bowel disease (IBD).
- Understanding the pandemic's differential impact across diverse healthcare settings, including high-income countries (HIC) and low- and middle-income countries (LMIC), is crucial.
- Previous research has not comprehensively compared COVID-19 outcomes in pediatric IBD patients between HIC and LMIC.
Purpose of the Study:
- To compare the clinical characteristics, disease activity, and management strategies of pediatric IBD patients with COVID-19 in HIC versus LMIC.
- To identify factors influencing disease severity and treatment accessibility in different economic contexts.
- To inform global health policies for improving care for pediatric IBD patients during pandemics.
Main Methods:
- A retrospective cohort study analyzing electronic health records of pediatric IBD patients diagnosed with COVID-19.
- Data collected included demographics, IBD type (ulcerative colitis [UC], Crohn's disease), disease activity indices (e.g., Paediatric Ulcerative Colitis Activity Index [PUCAL]), COVID-19 severity, and treatment interventions.
- Statistical analysis compared outcomes between patients from HIC and LMIC, controlling for relevant variables.
Main Results:
- Pediatric IBD patients in LMIC experienced significantly higher rates of severe COVID-19 and IBD flares compared to those in HIC.
- Access to advanced therapies and timely medical consultations was markedly lower in LMIC.
- Disparities in healthcare infrastructure and resources correlated with poorer clinical outcomes.
Conclusions:
- COVID-19 disproportionately affected pediatric IBD patients in LMIC, exacerbating existing health inequities.
- Urgent global initiatives are needed to strengthen healthcare systems and ensure equitable access to care for children with IBD in resource-limited settings.
- Pandemic preparedness plans must address the specific needs of vulnerable pediatric populations with chronic conditions.
Abbreviations:
COVID-19: Coronavirus disease 2019; HIC: high-income countries; IBD: inflammatory bowel disease; LMIC: low- and middle-income countries; PUCAL: paediatric ulcerative colitis activity index; SCD: sickle cell disease; UC: ulcerative colitis.
More Related Videos
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
08:23Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
Published on: November 5, 2019
Related Concept Videos
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...